Current and Emerging Therapeutic Strategies Targeting BCMA for Relapsed/Refractory Multiple Myeloma: Guidance for the Community Multidisciplinary Team

Get up to date on the latest evidence-based current and emerging strategies targeting BCMA in the care of patients with relapsed/refractory multiple myeloma with downloadable slides, an on-demand webcast, and a downloadable clinical practice resource.

Share

Program Content

Activities

BCMA-Targeting Strategies
Current and Emerging Therapeutic Strategies Targeting BCMA for Relapsed/Refractory Multiple Myeloma: Guidance for the Community Multidisciplinary Team
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 27, 2023

Activities

BCMA-Targeting Agents in MM
Current and Emerging Therapeutic Strategies Targeting BCMA for Relapsed/Refractory Multiple Myeloma: Guidance for the Community Multidisciplinary Team
Video
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2023

Expires: August 14, 2024

Activities

BCMA-Targeting Agents Resource
BCMA-Targeting Agents in Relapsed/Refractory Multiple Myeloma: Current Approved Indications and General Management of Toxicities
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 23, 2023

Faculty

cover img faculity

Carol Ann Huff, MD

Medical Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Oncology and Medicine
Multiple Myeloma Program
Johns Hopkins University School of Medicine
Baltimore, Maryland

cover img faculity

Suzanne Lentzsch, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Bristol Myers Squibb and Regeneron Pharmaceuticals, Inc.

Bristol Myers Squibb

Regeneron Pharmaceuticals, Inc